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targeted (44%) disease-modifying antirheumatic drug use; 84% reported current RA 
disease activity. Additional usable data were obtained including those on education, 
employment, health insurance, income, remission state, health assessment ques-
tionnaire, and patient global for the project. CONCLUSIONS: This analysis docu-
ments the feasibility of gaining rapid and relevant responses from a representative 
community RA patient population regarding their perspective on RA remission 
through our digital direct to patient portal.
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OBJECTIVES: Patient-reported outcome instruments are used in clinical trials of 
rheumatoid arthritis (RA) treatments to evaluate treatment benefits. A growing 
body of evidence suggests that joint pain, tiredness, and morning joint stiffness 
are among the most important symptoms for RA patients. A 7-item electronic 
daily diary was developed to assess these key symptom concerns of patients 
with RA for use as efficacy endpoints in clinical trials. The aim of this study was 
to evaluate the content of the diary and to ascertain whether patients with RA 
found items in the diary interpretable and relevant through concept elicitation and 
cognitive interviews. METHODS: A cross-sectional qualitative interview study was 
conducted in adults with moderate-severe RA in the US and UK. Interviews were 
conducted using a standardized interview guide to elicit information about ways 
patients with RA experience and talk about their symptoms followed by a cognitive 
interview on the dairy. Data were analyzed utilizing a qualitative analysis software 
program, Atlas.ti. RESULTS: The study sample included 28 participants (US n= 22, 
UK n= 6; 29% male; mean age 58.41 years; RA mean duration 13.92 years). Total 
HAQ-DI mean scores were 0.84 (US) and 1.50 (UK). Morning joint stiffness (n= 19), 
joint pain (n= 28), and tiredness (n= 7) were among the most commonly experi-
enced and reported symptoms; saturation of these concepts was achieved in the 
second interview. These results demonstrated that the diary includes appropriate 
content and terminology. Cognitive interviews indicated that participants found 
the diary items and response options clear, easy to understand and relevant to 
their RA experiences. No differences in qualitative results were noted between 
the two country samples. CONCLUSIONS: Results of this qualitative study sug-
gest that the 7-item electronic daily diary includes content relevant to patients 
and is suitable for assessing RA symptoms in clinical studies of patients with 
moderate to severe RA.
PMS72
doeS oral CholeCalCiferol SuPPleMentation iMProVeS Pain 
intenSity and diSability in PatientS with ChroniC low baCk Pain?
Bansal D.1, Ghai B.2
1National Institute of Pharmaceutical Education and Research, Mohali, India, 2Post Graduate 
Institute of Medical Education and Research, Mohali, India
OBJECTIVES: In the past decade many studies established relationship between vita-
min D deficiency and chronic musculoskeletal pain including low back pain. Present 
study aimed to examine the effect of vitamin D3 supplementation in patients with 
chronic low back pain with low level of vitamin D. METHODS: This single arm, open 
label study was conducted in a public tertiary care teaching hospital in India after 
obtaining approval from the Ethics Review Board of the hospital. Adult patients of 
either gender, aged 18 to 65 years, with a diagnosis of CLBP and low serum 25(OH)
D3 levels (< 30 ng/mL) and not responding to medications and physical therapies, 
having a pain score of at least 50 as assessed on 0 – 100 Visual Analogue scale (VAS) 
at baseline were eligible for study recruitment. Cholecalciferol (active vitamin D3) 
in a dose of 60,000 IU/week for a period of 8 weeks was given to the enrolled sub-
jects according to standard guidelines. Study endpoints include change in pain 
score and disability as measured by modified Oswestry disability questionnaire 
(MODQ). Patient information and outcome measures were collected at baseline, 2, 
3 and 6 months. RESULTS: A total of 68 chronic low back patients were included 
in the trial. Mean baseline vitamin D level is found to be 12.80+5.73 ng/ml. After 
treatment it significantly (P< 0.01) increased to 36.07+12.51. VAS (81.03+18.57) and 
MODQ (44.83+15.47) were high at baseline. Pain intensity has significantly reduced 
to 44.71+18.96 (< 0.05) and 35.74+17.75 (< 0.05) at 3 and 6 months respectively. 
Disability has significantly reduced to 30.94+12.48 (< 0.05) and 26.10+10.03 (< 0.05) 
at 3 and 6 months respectively. CONCLUSIONS: Present study shows that vitamin 
D supplementation can improve the pain and disability in patients with CLBP. Study 
results should be carefully interpreted as it is a single arm open label study and 
concomitant medication usage was not assessed.
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OBJECTIVES: Interpretation of patient-reported outcomes (PROs) requires some defi-
nition of an important or meaningful difference. This study aimed to estimate mini-
mally important differences (MIDs) for the Patient-Reported Outcomes Measurement 
Information System (PROMIS®) Fatigue and Pain Interference scale scores in rheu-
matoid arthritis (RA). METHODS: The responsiveness of several PROs was assessed 
in an observational cohort of 521 RA patients in the Arthritis, Rheumatism and Aging 
Medical Information Systems (ARAMIS) cohorts. PROMIS Fatigue and Pain Interference 
instruments were administered at baseline, 6 months, and 12 months. Self-reported 
retrospective changes in fatigue and pain over the previous 6 months were obtained at 
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OBJECTIVES: Perioperative pain management is an important aspect of recov-
ery from TKA, as severe pain can delay ambulation and hospital discharge. The 
objective of this study was to determine the impact of local infiltration analgesia 
using LB when compared to continuous femoral nerve catheter (FNC) following 
TKA. METHODS: This study enrolled consecutive patients who received a TKA 
between April 2011 and September 2014 into three study groups, excluding bilat-
eral and revision TKA. Study Group A received adductor canal infiltration with 
bupivacaine and knee infiltration with LB. Study Group B received adductor canal 
infiltration with LB and knee infiltration with LB. The control group received a con-
tinuous FNC with an OnQ pump and ropivacaine. Numeric pain rating scores (NPRS), 
distance walked, and length of stay (LOS) were the primary outcomes. RESULTS: 
A total of 237 participants were enrolled in this study, including 98 in Group A, 34 
in Group B, and 105 controls. On postoperative day (POD) 0, mean NPRS were simi-
lar between Group A (1.8±1.7), Group B (2.7±1.8), and the control group (2.3±2.4). 
Significantly (p< 0.05) more patients in Group A (58%) and Group B (44%) walked 
on POD 0 than in the control group (0%); almost all patients walked on POD1. The 
mean distance walked was also significantly greater (p< 0.05) on POD0 and on POD1 
in Group A (33±42 feet; 193±203 feet) and Group B (42±82 feet; 211±144 feet) than 
in the control group (0 feet; 46.3±73 feet). LOS was significantly (p< 0.05) shorter in 
Group B (2.2±1.7 days), than in the control group (3.2±0.7 days) and Group A (3.0±1.7 
days). CONCLUSIONS: Local infiltration analgesia using LB improved ambulation 
and LOS following TKA when compared to continuous FNC with an OnQ pump and 
ropivacaine. The one-day decrease of hospitalization suggests an estimated cost 
savings to an Illinois hospital of $2,158 per patient.
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OBJECTIVES: Fibrodysplasia Ossificans Progressiva (FOP) is a rare and disabling 
genetic condition of progressive extraskeletal bone formation. Physical function-
ing declines as FOP progresses. The objective was to develop a measure of physical 
function (PF) in adults with FOP. METHODS: We reviewed the PROMIS PF item bank 
for relevant items for FOP, and 44 PF items were identified. We then conducted 
concept elicitation (CE) interviews in 21 patients diagnosed with FOP (with varying 
levels of disease severity) who attended the International FOP Association meeting. 
The selected PF items were administered after the CE interviews. Interview data 
were analyzed to identify categories of physical functioning that were impacted by 
FOP. Based on the CE findings and PF item data, 26 items were initially selected for 
the new measure. Clinical experts in FOP reviewed the proposed set of items. Five 
additional items were incorporated into the draft measure, and cognitive interviews 
(CIs) were conducted in 10 patients, and revisions were made to the final FOP-PF 
Questionnaire (FOP-PFQ; 28 items). RESULTS: For the CE interviews, mean age was 
30 years (range 16–54) and 58% were female. For the CIs, mean age was 31 years 
(range 16–57) and 50% were female. CE interviews demonstrated substantial impacts 
of FOP on mobility, upper extremity function, and related activities. The CE findings, 
PROMIS PF item descriptive data, and discussion with clinical experts resulted in 
31 relevant items which were included in the draft FOP-PFQ. Based on the CIs, the 
majority of patients understood the instructions, questions, and response scales; 
three items were deleted due to redundancy or item removal from the original 
PROMIS item bank. CONCLUSIONS: This qualitative research supports the content 
validity of the FOP-PFQ and illustrates the application of PROMIS item banks for 
efficient new instrument development in an ultra-rare and disabling genetic disease.
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OBJECTIVES: Rheumatoid arthritis (RA) is an autoimmune disease characterized 
by significant morbidity related to systemic and joint inflammation. With the 
availability of more targeted therapeutic approaches and the potential of disease 
remission, there is increased focus on utilizing patient reported outcomes to better 
evaluate RA treatment impact. Collecting such data efficiently, i.e., with relatively 
low cost and time expenditures, can be challenging. Our objective was to imple-
ment digital direct-to-patient methodology to collect and incorporate United States 
(US) RA patient data into the Outcome Measures in Rheumatoid Arthritis Clinical 
Trials (OMERACT) project to study the patient perspective on remission. METHODS: 
Leveraging a known community (MediGuard.org) of approximately 40,000 US RA 
patients with pre-existing consent to contact for research purposes, patients were 
contacted in December 2014 to obtain 50 responses to the OMERACT survey through 
a direct-to-patient digital communications platform. Patients did not receive any 
honoraria for survey completion. RESULTS: The first survey was completed within 
seven minutes of initial digital outreach and the fiftieth within three hours. RA 
patients from 23 continental US states were represented. Of the 50 patients, 82% 
were female, mean age 54.8 years; male patients were older, mean age 61.7 years. 
RA diagnosis duration was 11.3 years average (range 1-40). Comorbidities includ-
ing other autoimmune and musculoskeletal conditions, diabetes, cardiovascular 
disease, malignancies were reported by 70%; 76% reported synthetic (72%) and/or 
